Edition:
United Kingdom

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

15.34USD
17 Jul 2018
Change (% chg)

-- (--)
Prev Close
$15.34
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
39,037
52-wk High
$23.36
52-wk Low
$5.31

Chart for

About

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its... (more)

Overall

Beta: 1.55
Market Cap(Mil.): $131.52
Shares Outstanding(Mil.): 16.06
Dividend: --
Yield (%): --

Financials

  GTXI.OQ Industry Sector
P/E (TTM): -- 85.48 32.76
EPS (TTM): -1.71 -- --
ROI: -196.34 2.29 14.61
ROE: -196.34 3.86 16.34

Deutsche Boerse beefs up forex business with $100 million buy

BERLIN Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million (75.5 million pounds) deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

30 May 2018

Deutsche Boerse beefs up forex business with $100 million buy

BERLIN Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

30 May 2018

Deutsche Boerse beefs up forex business with $100 mln buy

BERLIN, May 30 Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

30 May 2018

BRIEF-GTX Announces Early Completion Of Patient Enrollment In The Astrid Trial

* GTX ANNOUNCES EARLY COMPLETION OF PATIENT ENROLLMENT IN THE ASTRID TRIAL, A PHASE 2 CLINICAL TRIAL OF ENOBOSARM IN STRESS URINARY INCONTINENCE

09 Apr 2018

BRIEF-GTX Inc Q4 Loss Per Share $0.43

* GTX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

12 Mar 2018

BRIEF-GTx Announced New Data Demonstrating Enobosarm's Potential To Treat Stress Urinary Incontinence At SUFU 2018

* GTX ANNOUNCED NEW DATA DEMONSTRATING ENOBOSARM’S POTENTIAL TO TREAT STRESS URINARY INCONTINENCE AT SUFU 2018

05 Mar 2018

BRIEF-GTx Trial Results In Stress Urinary Incontinence Accepted For Podium Presentation At SUFU

* GTX PHASE 2 ENOBOSARM CLINICAL TRIAL RESULTS IN STRESS URINARY INCONTINENCE ACCEPTED FOR PODIUM PRESENTATION AT SUFU Source text for Eikon: Further company coverage:

22 Feb 2018

Earnings vs. Estimates